HEM Hemostemix Inc.
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Hemostemix (CVE: HEM)
›
Hemostemix (CVE: HEM) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.0300 CAD on 19 November 2026, down 72.7% over 52 weeks. Its 52-week range is 0.0300 CAD to 0.1100 CAD, and it trades at the bottom of that range.
Its market capitalisation is 6.34M CAD.
Hemostemix reports return on equity of 94.8% and an operating margin of 0.0%.
Its debt exceeds its cash by 3.37M CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 27 November 2026.